Glaukos touts Ph2 glaucoma trial for drug-eluting implant

Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost within the eye and when it’s depleted, the iDose is removed and replaced. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts Ph2 glaucoma trial for drug-eluting implant appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Glaukos Source Type: news

Related Links:

Publication date: Available online 30 March 2020Source: Microvascular ResearchAuthor(s): Aizhu Tao, Yuanbo Liang, Juanjuan Chen, Haishuang Hu, Qiangjie Huang, Jingwei Zheng, Cong Ye, Fan Lu
Source: Microvascular Research - Category: Biochemistry Source Type: research
AbstractPurpose of ReviewTo review the current understanding of the pathophysiology and management of aqueous misdirection syndrome.Recent FindingsAqueous misdirection syndrome represents a spectrum of disorders that converge on a common pathway of increasing posterior segment pressure and secondary angle closure glaucoma. Although the etiology of aqueous misdirection remains unclear and is likely multifactorial, recent data supports choroidal expansion as an inciting event in the pathogenesis of the syndrome. As such, the term aqueous misdirection may be a misnomer. Some would argue that the use of terminology such as acu...
Source: Current Ophthalmology Reports - Category: Opthalmology Source Type: research
Second Sight Medical Products is the latest medtech company to face tough losses as a result of the financial impact of the novel coronavirus (SARS-CoV-2). The Sylmar, CA-based company is laying off 84 of its 108 employees and said it intends to wind-down operations. The firm develops implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals. FDA greenlit the Argus II retinal prosthesis system in 2013. Plans now call for the Second Sight to retain an adviser experienced in winding down operations to guide the board on the next steps. Any wind down activity, if impl...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Business Source Type: news
Conditions:   Glaucoma;   Diabetic Retinopathy;   Refractive Errors;   Cataract;   Behavior, Health Interventions:   Other: No Financial Incentive;   Behavioral: Financial Incentive Sponsors:   University of Alabama at Birmingham;   Centers for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 28 March 2020Source: Autoimmunity ReviewsAuthor(s): Orna Geyer, Yoram Levo
Source: Autoimmunity Reviews - Category: Allergy & Immunology Source Type: research
AbstractPurposeTo evaluate the safety and the adjunctive effect of intracameral tissue plasminogen activator (tPA) in trabeculectomy for patients with primary open-angle glaucoma (POAG).MethodsThis was a prospective, randomized study consisting of patients with POAG who underwent trabeculectomy in Tel Aviv Medical Center between March 2013 and December 2014. Patients were randomly assigned to two groups: Group 1 underwent mitomycin C (MMC) trabeculectomy and group 2 underwent MMC trabeculectomy with intracameral tPA. Complete and overall success were defined as intraocular pressure (IOP) between 5 and 18  mmHg and at ...
Source: International Ophthalmology - Category: Opthalmology Source Type: research
This study was designed to measure retinal perfusion density changes on optical coherence tomography (OCT) angiography and OCT thickness alterations associated with acutely increased IOP after intravitreal injections. Methods: Retrospective observational clinical study of 40 eyes (39 patients) with various retinopathies from October 2016 to June 2017 at a tertiary care retina clinic in NYC. Patients were older than 18 years, with vision>20/100, able to fixate and without media opacities precluding OCT angiography, receiving intravitreal bevacizumab or aflibercept for diabetic retinopathy, retinal vein occlusion, macu...
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research
ZO-1 associates with α3 integrin and connexin43 in trabecular meshwork and Schlemm's canal cells. Int J Physiol Pathophysiol Pharmacol. 2020;12(1):1-10 Authors: Li X, Acott TS, Nagy JI, Kelley MJ Abstract Cellular structures that perform essential homeostatic functions include tight junctions, gap junctions, desmosomes and adherens junctions. The aqueous humor, produced by the ciliary body, passes into the anterior chamber of the eye and is filtered by the trabecular meshwork (TM), a tiny tissue found in the angle of the eye. This tissue, along with Schlemm's canal (SC) inner wall cells, is thoug...
Source: International Journal of Physiology, Pathophysiology and Pharmacology - Category: Physiology Tags: Int J Physiol Pathophysiol Pharmacol Source Type: research
Condition:   Primary Glaucoma Intervention:   Device: eyeWatch Sponsors:   dr. Kaweh Mansouri;   Manchester Royal Eye Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsBetter counselling of, and communication with, the patient would help increase their awareness regarding their condition and the care required. This has the potential to enable better compliance with and adherence to treatment. Standardized training of ophthalmologists to improve clinical diagnosis of glaucoma would also go a long way.
Source: International Ophthalmology - Category: Opthalmology Source Type: research
More News: Clinical Trials | Glaucoma | Medical Devices | Opthalmology | Travatan